Definitions
from The American Heritage® Dictionary of the English Language, 5th Edition.
- noun An oral hypoglycemic drug, C19H27NO3, that stimulates the release of insulin from the pancreas and is used to treat type 2 diabetes.
from Wiktionary, Creative Commons Attribution/Share-Alike License.
- noun A
meglitinide drug for the treatment of type IIdiabetes that lowersblood glucose by stimulating the release ofinsulin from thepancreas .
Etymologies
from The American Heritage® Dictionary of the English Language, 4th Edition
Support
Help support Wordnik (and make this page ad-free) by adopting the word nateglinide.
Examples
-
Effect of nateglinide on the incidence of diabetes and cardiovascular events.
Mark Hyman, MD: Millions Die Due to Withheld Medical Treatment MD Mark Hyman 2010
-
In fact, three of the newer medicines — acarbose and miglitol (both alpha-glucosidase inhibitors) and nateglinide (a meglitinide) — actually decrease HbA1c less than some of the older drugs.
-
In fact, three of the newer medicines—acarbose and miglitol (both alpha-glucosidase inhibitors) and nateglinide (a meglitinide)—actually decrease HbA1c less than some of the older drugs.
-
In addition to background therapy and a study-specific lifestyle modification program, patients were randomized to receive either valsartan, nateglinide, valsartan and nateglinide together, or placebo.
-
Neither valsartan nor nateglinide is currently indicated for the treatment of patients with IGT.
-
Group randomly assigned over 9000 individuals with impaired glucose tolerance who also had cardiovascular disease or risk factors for cardiovascular disease to take the drug nateglinide or a placebo up to three times a day.
WN.com - Articles related to Hypertension study reveals benefits of online tracking 2010
-
Conclusions Among persons with impaired glucose tolerance and established cardiovascular disease or cardiovascular risk factors, assignment to nateglinide for 5 years did not reduce the incidence of diabetes or the coprimary composite cardiovascular outcomes.
New England Journal of Medicine The NAVIGATOR Study Group 2010
-
Valsartan therapy did not show a reduction in the risk of cardiovascular events in this well-managed group of patients, while nateglinide-based therapy did not show a reduction in the incidence of new-onset diabetes or of cardiovascular events in this study population.
-
We evaluated the effect of nateglinide on the occurrence of three coprimary outcomes: the development of diabetes; a core cardiovascular outcome that was a composite of death from cardiovascular causes, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for heart failure; and an extended cardiovascular outcome that was
New England Journal of Medicine The NAVIGATOR Study Group 2010
-
The study assessed whether valsartan or the oral anti-diabetic agent nateglinide could delay progression to diabetes or reduce the incidence of cardiovascular events in people with IGT and cardiovascular disease or risk factors.
Comments
Log in or sign up to get involved in the conversation. It's quick and easy.